Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hans Meisen
Institutions:
City Of Hope National Medical Center,
City of Hope,
Beckman Research Institute
Observed institutions:
City Of Hope National Medical Center,
City of Hope,
Beckman Research Institute
ORCID:
0000-0001-7617-2819
Observed ORCID:
0000-0001-7617-2819
OpenAlex ID:
A5001029650
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors
2025
·
Miguel A. Villalona-Calero
, Lei Tian
, et al.
·
JCI Insight
·
16
PDF
Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer.
2022
·
Yuan Yuan
, Jianying Zhang
, et al.
·
Journal of Clinical Oncology
·
4
hNIS-based imaging to monitor treatment with the novel oncolytic virus CF33-hNIS-antiPDL1 in humans with advanced triple negative breast cancer
2025
·
Jamie Rand
, Dave Yamauchi
, et al.
·
Frontiers in Oncology
·
2
PDF
Abstract OT3-03-01: Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer
2023
·
Yuan Yuan
, Jamie G. Rand
, et al.
·
Cancer Research
·
2
A First-in-Human Dose Escalation Clinical Trial of Engineered Natural Killer Cell Therapy in Non-Small Cell Lung Cancer Patients Refractory to Immune Check Point Inhibitors
2024
·
Miguel A Villalona
, Lei Tian
, et al.
·
Blood
Abstract 6788: hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer
2023
·
Jamie Green Rand
, Dave Yamauchi
, et al.
·
Cancer Research
Show more works
View as search
Works count:
6
Citation count:
24
H-index:
2
I10-index:
1
Year
Topic
Type